When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

Meanwhile, for fiscal 2025, analysts expect Vertex Pharmaceuticals to report an adjusted EPS of $15.61, marking a significant improvement from the loss of $1.35 per share in fiscal 2024.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2025, and raised the low end of its ...

Vertex was founded in 1989 and has its global headquarters in Boston, ... SOURCE Vertex Pharmaceuticals (Canada) Inc. Share; Comments. Recommended For You. Related Analysis.

W hen Vertex Pharmaceuticals moved from Cambridge to Boston’s Seaport a decade ago, it signaled that what was then a sea of parking lots could be a booming business district, and galvanized a ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...

Vertex, the most valuable homegrown biotech in the state, had for months been considering vacating its 1.1 million-square-foot headquarters in the Seaport neighborhood. Skip to main content Sections ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...

Vertex Pharmaceuticals dominates the cystic fibrosis market with a promising pipeline and strategic M&A activity. Read why I rate VRTX stock a Buy now.

With a market cap of $122.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) operates as a global biotechnology company that develops and commercializes therapies for treating cystic fibrosis (CF).